Gilead Sciences, Inc. $GILD Holdings Lifted by Foundations Investment Advisors LLC

Foundations Investment Advisors LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 91,142 shares of the biopharmaceutical company’s stock after acquiring an additional 8,266 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Gilead Sciences were worth $10,117,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in shares of Gilead Sciences by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after purchasing an additional 1,893,401 shares in the last quarter. Geode Capital Management LLC grew its position in Gilead Sciences by 2.6% in the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after buying an additional 727,515 shares during the last quarter. Norges Bank bought a new position in shares of Gilead Sciences in the second quarter valued at $2,150,268,000. Invesco Ltd. lifted its position in shares of Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares during the last quarter. Finally, Amundi boosted its stake in shares of Gilead Sciences by 18.2% during the 2nd quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock worth $1,167,221,000 after acquiring an additional 1,614,355 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

NASDAQ GILD opened at $139.55 on Friday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The firm has a market capitalization of $173.14 billion, a price-to-earnings ratio of 21.64, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. The company has a 50 day simple moving average of $125.05 and a 200-day simple moving average of $119.38. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $141.71.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the prior year, the business earned $2.02 EPS. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on GILD shares. Rothschild & Co Redburn boosted their target price on Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Truist Financial upped their price objective on shares of Gilead Sciences from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday. Mizuho raised their target price on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Argus boosted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Finally, UBS Group raised their price objective on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $135.56.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Wolfe Research raised its price target to $155 (from $150) and kept an “outperform” rating — implying ~10% upside from current levels. Wolfe Research PT Raise
• Positive Sentiment: Citigroup published a bullish forecast for strong price appreciation, supporting demand expectations for GILD. Citigroup Forecast
• Positive Sentiment: Truist Financial also issued a forecast calling for meaningful upside, lining up with broader analyst optimism. Truist Forecast
• Positive Sentiment: BMO Capital Markets added to the chorus of bullish forecasts, which reinforces analyst-driven buying interest. BMO Forecast
• Positive Sentiment: UBS reiterated expectations for upside, further supporting consensus that GILD’s fundamentals and pipeline justify higher valuations. UBS Note
• Positive Sentiment: Coverage pieces (BarChart, Zacks interest) note that Gilead has outperformed the market and that analysts are broadly optimistic — positive sentiment that can attract momentum flows. BarChart Analysts Overview
• Neutral Sentiment: Zacks flagged increased investor attention to GILD (tracking user searches), which can boost volume but is not a directional catalyst by itself. Zacks Attention Note
• Neutral Sentiment: Reported short-interest data is inconsistent (entries show increases but list 0 shares / NaN), suggesting a data glitch — no clear short-squeeze or heavy shorting signal from this report.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares at ~$139.89 (≈$1.4M), trimming his holding ~1.76%. Insider sales can be read negatively by some investors even if part of routine diversification. SEC Form 4

Insiders Place Their Bets

In other news, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the completion of the sale, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at $76,504,230. This trade represents a 16.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the sale, the chief financial officer owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. This represents a 1.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 257,397 shares of company stock valued at $33,385,512 in the last three months. Company insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.